dr. le on the rationale for tepotinib in metex14-mutant nsclc
Published 4 years ago • 344 plays • Length 1:54Download video MP4
Download video MP3
Similar videos
-
1:13
dr. reckamp on pivotal data in metex14-altered nsclc
-
1:30
dr. drilon on tepotinib and gefitinib in met egfr-mutant nsclc
-
8:04
fda priority review of capmatinib for metex14-mutated nsclc
-
6:13
vision: tepotinib in met exon 14 skipping nsclc
-
0:56
oncologist’s opinion on the drugs for review capmatinib, tepotinib, crizotinib, and cabozantinib.
-
7:47
mycobacterial lung infection: a big name for a serious problem - dr. julie philley
-
3:13
hearing loss: one-in-five americans affected
-
5:07
christie’s story: metastatic lung cancer survivor
-
0:49
the importance of metex14 testing in nsclc
-
2:49
the challenges of treating metex14 nsclc
-
3:05
tepotinib in metex14 skipping alteration nsclc
-
13:06
met exon 14 mutations in mnsclc
-
11:53
insight 2: a phase ii study of tepotinib plus osimertinib in met-amplified nsclc
-
2:48
vision trial: subset efficacy analyses of tepotinib for nsclc
-
0:58
vision trial produces positive data in nsclc with met exon 14 mutations
-
2:40
dr. halmos on met mutations in patients with nsclc
-
5:15
"advancements in treatment sequencing: tepotinib in metex14 nsclc | dr. kripa bajaj | crsf 2023
-
2:10
dr linscott on the need for improved mrd detection in high-risk nmibc
-
1:04
tepotinib: advanced non-small cell lung cancer
-
3:35
the availability of met inhibitors for nsclc
-
2:47
key points about met in lung cancer
-
2:24
dr. reckamp on met-targeting strategies in nsclc